As yet the investigators do not understand if there are biomarkers of immune protection after the Flumist or Live Attenuated Flu Vaccine (LAIV). Here the investigators test the hypothesis that the T-bet expressing fraction of flu-specific B cells after live attenuated influenza vaccination also serves as an early biomarker of long-lived antibody responses after vaccination. In this study the investigators will be providing the LAIV to up to 10 healthy subjects and assaying their immune response and then providing the intramuscular influenza vaccination and testing to see if the immune protection after the LAIV also protects after the intramuscular influenza vaccination. Update: We have amended this protocol to study the antigen-specific B cell populations that circulate after LAIV or IIV prime and LAIV or IIV boost.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Outcome Measure: Participants with a positive T-bet expressing Flu-specific B cell subtype
Timeframe: Baseline
Outcome Measure: Participants with a positive T-bet expressing Flu-specific B cell subtype
Timeframe: 7 days post first injection
Outcome Measure: Participants with a positive T-bet expressing Flu-specific B cell subtype
Timeframe: 14 days post first injection
Outcome Measure: Participants with a positive T-bet expressing Flu-specific B cell subtype
Timeframe: 7 days post second injection